Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
about
Inherited heart disease - what can we expect from the second decade of human iPS cell research?Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse ChemotherapeuticsHigh-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Modeling Inherited Arrhythmia Disorders Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes.21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells.iPSC-derived cardiomyocytes reveal abnormal TGF-β signalling in left ventricular non-compaction cardiomyopathy.VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.Dalbergioidin Ameliorates Doxorubicin-Induced Renal Fibrosis by Suppressing the TGF-β Signal PathwayDoxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes.Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome.Clinical Trials in a DishCombinatorial Extracellular Matrix Microenvironments for Probing Endothelial Differentiation of Human Pluripotent Stem Cells.Circadian networks in human embryonic stem cell-derived cardiomyocytes.Patient-derived induced pluripotent stem cells in cancer research and precision oncology.Induced pluripotent stem cells, past and future.Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.A BAG3 chaperone complex maintains cardiomyocyte function during proteotoxic stress.TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy.Recent Advances in Understanding and Managing Cardiomyopathy.Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies.Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes.Prospects and Frontiers of Stem Cell ToxicologyFunctional TASK-3-Like Channels in Mitochondria of Aldosterone-Producing Zona Glomerulosa Cells.Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs.Impact of regulatory variation across human iPSCs and differentiated cells.Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy.Multiscale technologies for treatment of ischemic cardiomyopathy.Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Platform for Testing For Drug Cardiotoxicity.Pluripotent Stem Cell-Derived Human Tissue: Platforms to Evaluate Drug Metabolism and Safety.MUSCLEMOTION: A Versatile Open Software Tool to Quantify Cardiomyocyte and Cardiac Muscle Contraction In Vitro and In Vivo.Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms.Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.A PET/MR Imaging Approach for the Integrated Assessment of Chemotherapy-induced Brain, Heart, and Bone Injuries in Pediatric Cancer Survivors: A Pilot Study.
P2860
Q54584742-D1D9F697-3BD3-42E4-AD9C-7309755225BBQ54602868-C2B7E9E8-4FA0-4847-A37A-1E325FADCE0DQ54603710-926D66B2-D512-4E53-9E64-7166B8A0A775Q54604002-03AFA08B-F21C-4FEA-BA9F-74A2AF8BB9EDQ54604329-865A8BF5-9369-413F-8EA7-7A461CFB041EQ54604394-17F9686B-6431-4655-88A6-AD4E65E0AC51Q54604401-3D3E85BD-BC8F-4636-83F3-6AFBF9149D16Q54604971-048D5B82-A1D1-4B34-917E-9B7228AAF417
P1343
Q28079217-2B05578E-2A8B-4FA9-943E-7C576D0DE89BQ29027136-230A2E93-382B-44C5-82DA-F32F27C58603Q30847302-730D85E6-344F-4347-B755-B1FAA939A197Q33704567-B15EA605-4A8B-465A-81F1-300C54BD2F26Q33900003-8F963108-07A1-442E-9AEA-170324C8AADCQ37228986-4C439F09-CF0F-47EC-B4E9-0D03E5B12ED6Q37297762-C1976C14-9284-4659-90B4-E72EF3575123Q37469455-A7681E33-7001-4327-9897-72AC1FC73EBCQ37558117-AD37A31E-E6CF-4B3F-BBF5-5EE3F90093F4Q37704467-A8B0A79C-8360-455F-B73F-EBDB715BCBAFQ37730325-3C707BEE-850A-4DE6-95FF-E579850C9E36Q37737063-BD955AE0-6100-4FD9-8AA2-649ED7C35572Q38659139-22B1867A-8918-405A-8357-02D55CD2108EQ38768295-87230F8F-D11D-4F1A-A498-E49B1BB926D8Q38786566-88CD4AB0-29F0-48B5-8D26-7DF26BFE6AB9Q38814985-45064592-4A24-4323-AAF5-F32224A4BD0DQ38819976-CB00B695-AD0A-413D-A56A-E4FB1ABF62B0Q38823143-A30CE493-7051-4A0E-9C70-1191683536C3Q38874111-302A968D-8288-4718-8C39-0065E908DDD0Q38890930-0BA5DBE7-28D5-4B92-8C5C-884C6E649289Q39050993-4EA6C3C6-077A-4048-B87B-3645B98BE8EFQ39078275-1022B8DE-FA1D-4D26-906E-2B60900F644EQ39231153-21F1FF44-9EA1-4F21-8B8A-D5D7C6B2DD3CQ41068105-405999CE-8D2C-42A8-894E-20ADBF683F70Q41252402-E5426ECD-1204-4386-BF83-9D26D1E4D1D4Q41528372-84D9E7FA-5CE8-445A-99A3-D91E8C6D9E08Q41664792-5836F378-7197-4173-BBA9-BE28EC8A94ACQ41869132-6B18CCFD-96B0-49B1-9F10-DF04D6F190F3Q42603119-ABDB390A-E490-4360-BB2B-1AA399C1926BQ45061685-BCD9199D-60DF-483E-9FA7-227267386A4DQ45875404-307D7A19-1FC7-4B1C-B3F2-9516A4451EEEQ45990501-0AA2B116-B0FE-4E14-AF3D-3BBADAA41C05Q46276263-18DAE00B-7BC3-4096-8541-986E04AF7D25Q46454164-D52CF883-FD67-42B2-9BEF-C06D8D674093Q46801702-C914BCF2-53FE-4B70-8414-C4029B6683CFQ47225797-411EB296-6770-4B25-9D10-81DF4EC11458Q47241525-0BE84D5F-4871-4B38-B27F-4DC2BF47F244Q47557278-B807843D-1E6F-4E7B-9FB4-0E1A76922891Q48151662-FC59B78E-8B67-42AA-A8B5-324499D89431Q48166171-BDC48D65-43EA-42E1-BB67-D11626936267
P2860
Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human induced pluripotent stem ...... ubicin-induced cardiotoxicity.
@en
Human induced pluripotent stem ...... ubicin-induced cardiotoxicity.
@nl
type
label
Human induced pluripotent stem ...... ubicin-induced cardiotoxicity.
@en
Human induced pluripotent stem ...... ubicin-induced cardiotoxicity.
@nl
prefLabel
Human induced pluripotent stem ...... ubicin-induced cardiotoxicity.
@en
Human induced pluripotent stem ...... ubicin-induced cardiotoxicity.
@nl
P2093
P2860
P4510
P50
P921
P356
P1433
P1476
Human induced pluripotent stem ...... ubicin-induced cardiotoxicity.
@en
P2093
Alex C Chang
Alexandra Holmström
Antje D Ebert
Daniel Bernstein
Elena Matsa
Helen M Blau
Joseph C Wu
Joshua W Knowles
Melinda L Telli
P2860
P2888
P304
P356
10.1038/NM.4087
P407
P577
2016-04-18T00:00:00Z
P6179
1035585553